Venus Remedies Ltd, a research-based global pharmaceutical company, has launched its novel antibiotic adjuvant entity (AAE) to combat antimicrobial resistance caused by MDR, ESBL producing strains under the brand name ELORES.
It is effective against even the toughest carbapenemase resistant metallobetalactamses and it shows outstanding results as it not only kills resistant pathogens (bacteria) but also prevents the spread of resistance.
CSE1034 ELORES comprises of a third generation cephalosporin, a beta lactamase inhibitor along with non antibiotic adjuvant disodium edetate for intravenous administration. It is effective against MDR pathogen producing ESBLs, MBLs like NDM-01, increases cell permeability while working on cell impermeability mechanism of MDRs, regulate 'Efflux pump over expression', breaks bacterial 'Biofilms', prevents 'transfer of resistant plasmid' and hence the spread of resistance is controlled.
Designed specifically to target growing bacterial resistance mechanisms, ELORES has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance. The product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics. It is also unique in its way that it not only kills resistant pathogens (Bacteria) but also prevents the spread of resistance.
The product was launched by Dr K N Parsad, associate professor, Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow at Manthan 2013, a seminar-cum-workshop organised by 'Venus Medicine Research Centre' (VMRC). The single-session seminar-cum-workshop was chaired by Dr Yatin Mehta, chairman, Medanta Institute of Critical Care and Anaesthesiology, Medanta The Medicity, Gurgaon, Haryana which was also attended by the eminent doctors from the healthcare fraternity of India.
At the unveiling ceremony of ELORES, Dr Manu Chaudhary, joint managing director and director- Research, Venus Remedies Limited said, “Receiving US patent for ELORES was a landmark development to initiate the process of commercialisation and today we are launching it in India as ELORES.”
The Company is positioning ELORES as the need of the hour as it would be able to reduce a minimum of 30 per cent of the hospitalisation cost and almost 50 per cent of the drug cost, thereby proving to be very beneficial for the patients.
It took Venus almost 10 years of constant hard work and dedication to develop this breakthrough technology. The Company has conducted Clinical Trials phase I, II and III successfully on a large patient population of 654 patients to prove clinical efficacy and safety in ESBL/MBL resistant pathogens.
Speaking on this occasion, Pawan Chaudhary, chairman and managing director, Venus Remedies Limited said, “ELORES is a novel product with a unique technology specifically addressing the compounding medical emergency of Antimicrobial Resistance, and thus there is no direct competition as such. However, products like meropenem and pipracillin+tazobactum are the closest in contested category though they are also getting huge resistance.”